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Aldehyde dehydrogenase (ALDH) is a cancer stem cell marker. Retinoic acid has antitumor properties, including the induction of
apoptosis and inhibition of proliferation. Retinal, the precursor of retinoic acid, can be oxidized to retinoic acid by dehydrogenases,
including ALDH. We hypothesized that retinal could potentially be transformed to retinoic acid with higher efficiency by cancer
stem cells, due to the higher ALDH activity. We previously observed that ALDH activity is greater in highly metastatic K7M2
osteosarcoma (OS) cells than in nonmetastatic K12 OS cells. We also demonstrated that ALDH activity correlates with clinical
metastases in bone sarcoma patients, suggesting that ALDH may be a therapeutic target specific to cells with high metastatic
potential. Our current results demonstrated that retinal preferentially affected the phenotypes of ALDH-highK7M2 cells in contrast
to ALDH-low K12 cells, which could bemediated by the more efficient transformation of retinal to retinoic acid by ALDH in K7M2
cells. Retinal treatment of highly metastatic K7M2 cells decreased their proliferation, invasion capacity, and resistance to oxidative
stress. Retinal altered the expression of metastasis-related genes.These observations indicate that retinal may be used to specifically
target metastatic cancer stem cells in OS.
1. Introduction
Retinoids are a class of compounds comprised of several
signaling molecules, such as retinoic acid and retinaldehyde,
that are structurally related to vitamin A (retinol) [1]. These
molecules play a crucial role in the regulation of various cel-
lular processes. Retinoids have been shown to exert a tumor-
suppressive effect on cells based on their interaction with
cyclins and cyclin-dependent kinases (CDKs) to prevent cell-
cycle progression [1]. Additionally, they also influence cancer
cell differentiation and apoptosis [2].Many cancers have been
shown to have abnormally low levels of various retinoids.
Retinoic acid, a derivative of retinol, has been shown
to inhibit proliferation of malignant tumors and induce
the apoptosis and differentiation in various types of cancer
cells [1, 3–6]. Due to retinoic acid’s antitumor properties,
its role is being investigated in the treatment of various
malignancies [3]. It is currently used in the treatment of
acute promyelocytic leukemia and has been shown to result
in complete remission [7]. Retinoic acid is derived from its
precursor, all-trans-retinal (also called retinaldehyde or vita-
min A aldehyde), by the action of dehydrogenases, including
aldehyde dehydrogenase (ALDH) [8]. Previous studies have
demonstrated that high ALDH activity predicted poor sur-
vival in various types of cancers [9, 10], such as breast cancer
[11], epithelial cancer [12], and sarcoma [13]. ALDH activity
is often specifically upregulated in cancer stem cells and has
been recognized as a marker for cancer stem cells [10, 14–
16]. Therefore, we believe it is reasonable to hypothesize that,
because of the higher ALDHactivity in cancer stem cells, reti-
nal could be more efficiently transformed to retinoic acid by
cancer stem cells, and thus preferentially induce the apoptosis
and alteration of these cells.
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Osteosarcoma (OS) is the most common primary tumor
of the bone. It has a bimodal age distribution with a major
peak during the second decade of life and a second smaller
peak observed in patients over 50 years old. The lung is the
most common site of metastatic spread, and survival is ulti-
mately determined by the presence of absence of pulmonary
metastatic disease. Deaths related to OS are thus the result of
metastasis to the lung rather than the primary tumor itself.
The prognosis of patients with OS has not improved in the
past several decades due to the lack of treatment specifically
targeting OS cell metastatic potential. Due to our limited
understanding of the biology of sarcoma metastasis, this
problem remains unsolved.
We have demonstrated the role of various cytokines and
signaling pathways in OS metastasis using two related cell
populations of a spontaneously occurring murine OS [17–
20]. These cell lines, K12 and K7M2, differ in their metastatic
potential, with K7M2 showing more features of cancer
stem cells and a much greater metastatic rate to the lungs
compared to K12 cells. The difference in their characteristics
and metastatic potentials demonstrated that K7M2 and K12
feature different activation statuses of multiple biologic fac-
tors and signaling pathways: ALDH, Notch1, andmammalian
target of rapamycin (mTOR). The inhibition of these sig-
naling pathways alters OS cell behavior in vitro [17–20]. We
observed that K7M2 cells demonstrated greater ALDH gene
expression and activity than the less metastatic K12 cells.
Additionally, ALDH activity was found to be greater in cul-
tured cells frombone sarcoma patients who experienced clin-
ical metastasis [21]. We thus hypothesized that ALDH might
represent a means to specifically target sarcoma cells with
high metastatic potential.
Our current research investigates the effect of novel
treatment approaches to thesemetastasis-related genes. In the
present study, we sought to take advantage of the increased
level of ALDH activity in highly metastatic K7M2 OS cells
to study the effects of retinal on cell growth and metastasis.
Given the ability of retinal to be transformed into retinoic
acid by ALDH and the high level of expression of ALDH in
cancer stem cells, we hypothesized that treatment with reti-
nal would selectively induce apoptosis and suppress tumor
growth in K7M2 OS cells.
2. Materials and Methods
2.1. Cell Culture and Retinal Treatment. K12 and K7M2 cells
were cultured in proliferation medium (10% FBS in DMEM).
5,000 cells were seeded in each well of a 12-well plastic plate.
Cells were treatedwith either 1𝜇g/mL or 5𝜇g/mL of all-trans-
retinal (Sigma) dissolved in 1mL of proliferation medium.
K7M2 cells treatedwith 1𝜇L ofDMSO served as control. Cells
were incubated for 2 days, before being fixed for observation
or harvested for mRNA isolation.
2.2. Fluorescence-Activated Cell Sorting (FACS) Analysis of
ALDH Activity and Sorting of Cells. ALDH enzymatic activ-
ity was determined using the Aldefluor Kit (STEMCELL
Technologies). Cultured K7M2 cells from treatment as well
as control groups were resuspended in Aldefluor buffer
Table 1: Primer sequences.
Gene Primer sequence
GAPDH Forward: TCCATGACAACTTTGGCATTG
Reverse: TCACGCCACAGCTTTCCA
Notch1 Forward: GCCGCAAGAGGCTTGAGAT
Reverse: GGAGTCCTGGCATCGTTGG
Hes1 Forward: CCAGCCAGTGTCAACACGA
Reverse: AATGCCGGGAGCTATCTTTCT
BMP2 Forward: TCTTCCGGGAACAGATACAGG
Reverse: TGGTGTCCAATAGTCTGGTCA
Akt1 Forward: ATGAACGACGTAGCCATTGTG
Reverse: TTGTAGCCAATAAAGGTGCCAT
cMyc
Forward:
TGACCTAACTCGAGGAGGAGCTGGAATC
Reverse:
AAGTTTGAGGCAGTTAAAATTATGGCTGAAGC
ALDH1 Forward: GACAGGCTTTCCAGATTGGCTC
Reverse: AAGACTTTCCCACCATTGAGTGC
Klotho Forward: CCCAAACCATCTATGAAAC
Reverse: CTACCGTATTCTATGCCTTC
(1× 106 cells/mL) and incubated at 37∘C as permanufacturer’s
instructions. During the cell sorting process, cells were
washed in Aldefluor buffer and maintained at 4∘C. FL1 chan-
nel of a BD FACSAria Cell Sorting System and FACSDiva
software (version 6.1.2; Becton, Dickinson and Company, San
Jose, CA) was used to assess ALDH activity. Fluorescence-
activated cell sorting (FACS) was utilized to collect cells
according to their fluorescence intensity, which corresponds
to cells’ ALDH activity level. Cells with high and low ALDH
levels were separately isolated and cultured.
2.3. Semiquantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR). RNeasy plus mini kit (Qiagen) and the
iScript cDNA Synthesis kit (Bio-Rad) were used to extract
RNA from the cells and generate cDNA, respectively. RT-PCR
was performed using a Bio-Rad MyiQ thermal cycler (Bio-
Rad). Table 1 shows the sense and antisense primers for RT-
PCR and their product. Following cycling parameters were
used for all reactions: 94∘C for 5 minutes; 30 cycles of the fol-
lowing: denature for 45 seconds at 95∘C, anneal for 30 seconds
(53∘C–56∘C), and extend for 45 seconds at 72∘C. Expression
of target genes was normalized to the expression of GAPDH,
which served as a control gene. ImageJ software (version 1.32j,
National Institutes of Health, Bethesda,MD)was used to per-
form RT-PCR analysis. The integrated density of bands was
calculated based on product of the area and the mean gray
value. All molecular bands were normalized to GAPDH.
2.4. Cell In Vitro Invasion Assay. In vitro invasion capacity of
K7M2 cells treated with retinal was compared to control cells
using a real-time cell invasion andmigration (RT-CIM) assay
system (ACEA Biosciences, Inc.), with a 16-well transwell
plate (CIM-plate 16, Roche Diagnostics GmbH). The surface
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of the wells in the upper chamber was coated with Matrigel
(BD BioSciences, Bedford, MA, USA) of different concentra-
tions (2.5%, 5%, and 10%). Serum-containing medium (10%
FBS) was added to the wells of the lower chamber. Cells (4 ×
104 per well) in serum-free mediumwere seeded in the upper
chamber.Themigration of the cells through theMatrigel was
monitored by the system every 15 minutes for 24 hours. Data
analysis was carried out using RTCA Software 1.2 supplied
with the instrument.
2.5. Actin Staining. Cells from each group were treated with
phalloidin conjugated with Alexa Fluor 488 (Invitrogen) to
observe actin organization. Treatment and control cells were
grown overnight in proliferation medium in 12-well plates
(50,000 cells/plate).The following day, the plates werewashed
twice with PBS, fixed in 3.7% formaldehyde solution for 10
minutes at room temperature, and washed two more times
with PBS. The cells were then permeabilized in 0.1% Trition
X-100 for 20 minutes and washed again with PBS. 5𝜇L of
methanolic stock solution phalloidin, 200𝜇L PBS, and 1%
BSAwere added to eachwell and allowed to stand for 20min-
utes, before being washed again with PBS. 300𝜇L of 300 nM
DAPI was used for nuclear staining.
2.6. Statistical Analysis. Statistical analysis of all experiments
for this study was carried out using data from at least three
samples from each treatment group. Statistical significance
was evaluated using Student’s 𝑡-test. Difference between
groups was considered significant for 𝑝 value <0.05.
3. Results
3.1. Retinal Treatment of Highly Metastatic K7M2 Cells
Decreased the Proliferation Capacity and Resistance to Oxida-
tive Stress. K7M2 cells have been shown to feature much
higher ALDH activity compared with K12 cells [17, 18]. K7M2
cells treated with all-trans-retinal (5𝜇g/mL) for 2 days were
observed to have fewer cells on the culture dishes compared
with the nontreated K7M2 cells (Figure 1(a)). Actually, com-
pared to retinal-treated K12 cells, the proliferation of retinal-
treated K7M2 cells was muchmore obviously decreased (Fig-
ure 1), indicating preferentially increased apoptosis in retinal-
treated K7M2 cells. Furthermore, retinal-treated K7M2 cells
also displayed higher levels of apoptosis induced by exposure
to hydrogen peroxide (250𝜇M, 1 hr), as seen by propidium
iodide (PI) staining (data not shown). Our previous results
have shown that the sorted ALDH-high K7M2 cells are more
resistant to oxidative stress-induced cell death, compared
with the sorted ALDH-low cells [17]. Treatment of ALDH-
highK7M2 cells with retinal (5𝜇g/mL) for 2 days significantly
increased the ratio of apoptotic cells induced by exposure to
hydrogen peroxide, compared to nontreated control ALDH-
high K7M2 cells (Figure 2). The apoptotic effect was much
more pronounced than inALDH-lowK7M2 cells.This obser-
vation indicates that the resistance to oxidative stress ofK7M2
cells was preferentially decreased by retinal in cells with high
ALDH activity.
3.2. Retinal Treatment of K7M2 Cells Resulted in Modified
Gene Expression of Metastasis-Related Factors and Reduced
ALDH Activity. Semiquantitative PCR analysis of K7M2
cells with and without retinal treatment was carried out to
compare the expression levels of various signaling molecules
involved in cell proliferation, apoptosis, and metastasis.
Treatment with retinal resulted in the downregulation of
Notch signaling as evidenced by decreased expression of
Notch1 and Hes1. Further, there was also a decrease in bone
morphogenetic protein 2 (BMP2), cMyc, and ALDH levels
while Klotho, a tumor suppressor, was up-egulated with
retinal treatment (Figure 3(a)). Additionally, ALDH activity
assay of K7M2 cells verified that retinal treatment (both 1𝜇g/
mL and 5 𝜇g/mL) was able to reduce the ALDH activity of
K7M2 cells (Figure 3(b)).
3.3. Retinal Treatment of K7M2 Cells Altered Cell Morphologi-
cal Characteristics andDecreased InvasionCapacity. Our pre-
vious results demonstrated that K7M2 cells feature different
cell morphology than K12 cells and have significantly higher
migration and invasion capacities in vitro [17, 18]. Here, actin
staining by phalloidin demonstrated that K7M2 cells treated
with retinal had undergone obvious alterations in migration-
related cell morphological characteristics with reduced
appearance of invadopodia, which play critical roles in cell
migration/invasion (Figure 4(a)). Finally, in vitro invasion
assays further displayed that treatment of K7M2 cells with
retinal (5 𝜇g/mL, 2 days) resulted in decreased cell invasion
compared with untreated cells (Figure 4(b)).
4. Discussion
All-trans-retinal is a precursor of retinoic acid and can be
transformed into retinoic acid by dehydrogenases, including
ALDH. Retinoic acid has been shown to induce differenti-
ation of hematopoietic and neural stem cells. Retinoic acid
appears to induce apoptosis and differentiation in a number
of cancers and has been successfully used to treat acute
promyelocytic leukemia [1, 7]. However, the role of retinal as
an antiproliferative agent in OS has not been studied. Based
on the fact that retinal can be transformed to retinoic acid by
ALDH, and ALDH activity is typically higher in cancer stem
cells [9, 15, 18], we investigated the effect that retinal would
have on highly metastatic OS cells.
Our study revealed that retinal was able to preferen-
tially target the highly metastatic K7M2 cells which feature
greater ALDH activity and other stem cell characteristics, by
repressing their proliferation and inducing the apoptosis of
these cells. The role of retinal in decreasing cell proliferation
and cell survival was demonstrated by exposing cells to
oxidative stress using hydrogen peroxide. ALDH-high K7M2
cells exhibited a greater increase in apoptosis compared to
ALDH-lowK7M2cells. Additionally, ourRT-PCR results also
showed that retinal treatment results in the downregulation
of various genes involved in cell-proliferation and cell sur-
vival. Namely, the expression level of Notch1, Hes1, cMyc, and
BMP2 was decreased in a dose-dependent manner. Further,
therewas anupregulation ofKlotho, a tumor suppressor gene.
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Figure 1: Retinal treatment of K7M2 cells decreased cell proliferation or survival. (a) and (b) The cell proliferation or survival capacity of
K7M2 cells was more reduced with retinal treatment (5 𝜇g/mL, 2 days), compared to K12 cells.
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Figure 2: Retinal treatment of sorted ALDH-high K7M2 cells decreased antioxidative stress capacity. After cell sorting according to ALDH
activity, it showed that the K7M2-ALDH high cells were more resistant to oxidative stress (H
2
O
2
, 250 𝜇M for 1 hr) than the K7M2-ALDH
low cells, while the retinal treatment of K7M2-ALDH high cells was able to greatly decrease their resistance to oxidative stress and resulted
in more cell apoptosis. “∗” indicates that ALDH-high control cells are significant different (𝑝 < 0.05) compared to ALDH-low control cells;
“∗∗” indicates retinal treated ALDH-high or ALDH-low cells are significant different (𝑝 < 0.05) compared to nontreated ALDH-high or
ALDH-low control cells, respectively.
Additionally, use of retinal as a therapeutic agent not only
employs the antiproliferative properties of retinoic acid but
also takes advantage of certain factors produced by tumor
stem cells specifically. The action of retinal on the cells is
mediated by retinoic acid [2]. Given that the conversion of
retinal to retinoic acid requires the action of dehydrogenases,
it can be expected that the activity of retinal will be higher
in tumor stem cells, which produce much higher quantities
of ALDH, thereby making retinal therapy highly specific.
Our results, therefore, indicate that retinal may be used as a
cellular “Trojan Horse” of sorts to specifically target cancer
stem cells.
Since pulmonary metastasis is the major cause of mortal-
ity in OS patients, it is crucial to devise therapeutic options
that specifically target the metastatic potential of OS cells.
Actin staining was performed to characterize the changes in
cell morphology following treatment with retinal. We have
previously demonstrated that changes inK7M2 cell shape and
appearance of invadopodia relate to alteration in cells’ migra-
tion/invasion potentials [17–21]. Our results demonstrate that
in addition to acting as an antiproliferative agent, retinal
also decreased cell invasiveness. Based on these results, we
conclude that retinal therapy has the potential to specifically
target metastatic OS cells and thus potentially decrease the
incidence of pulmonary metastases, the ultimate cause of
mortality in OS.
One of the limitations of this study is that the results
are based on experiments carried out in vitro. While several
studies have verified that the behavior of K7M2 cells parallels
the growth of humanOS cells, it is essential to conduct in vivo
studies in order to validate these results.
5. Conclusion
Our current results demonstrate that retinal was capable of
specifically acting on OS cells which express high levels of
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Figure 3: Retinal treatment of K7M2 cells modified the expression of metastasis-related genes and reduced ALDH activity. (a) RT-PCR
results showed retinal treatment of K7M2 cells (1 or 5 𝜇g/mL for 2 days) modified the expression of some key genes related with metastasis
or tumorigenesis. (b) ALDH activity assay showed that retinal treatment of K7M2 cells reduced the aLDH activity of the cells.
ALDH and promoted these cells to undergo apoptosis. As
cancer stem cells typically feature high ALDH activity, retinal
could be used to specifically repress the growth of cancer stem
cells with enhanced metastatic potential. Our study is the
first to demonstrate the potential application of retinal for the
treatment of tumorigenesis. We suggest that retinal could be
potentially used to target OS cells with stem-like properties
and ultimately decrease the ability of these cells to metasta-
size.
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Figure 4: Retinal treatment of K7M2 cells changed migration-related cell morphological characteristics and decreased migration capacity.
(a) Actin staining with phalloidin revealed that the cell morphology of K7M2 cells was modified with retinal treatment (5 𝜇g/mL for 2 days),
showing reduced presence of invadopodia. (b) In vitro invasion assay with 3D-matrigel (2.5%) revealed that K7M2 cells treated with retinal
treatment (5𝜇g/mL for 2 days) migrated slower than nontreated K7M2 control cells.
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